Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy

J Biomed Opt. 2013 Dec;18(12):120504. doi: 10.1117/1.JBO.18.12.120504.


The use of in vivo contrast-enhanced magnetic resonance (MR) imaging as a surrogate for photosensitizer (verteporfin) dosimetry in photodynamic therapy of pancreas cancer is demonstrated by correlating MR contrast uptake to ex vivo fluorescence images on excised tissue. An orthotopic pancreatic xenograft mouse model was used for the study. A strong correlation (r = 0.57) was found for bulk intensity measurements of T1-weighted gadolinium enhancement and verteporfin fluorescence in the tumor region of interest. The use of contrast-enhanced MR imaging shows promise as a method for treatment planning and photosensitizer dosimetry in human photodynamic therapy (PDT) of pancreas cancer.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Contrast Media / chemistry
  • Contrast Media / pharmacokinetics*
  • Contrast Media / therapeutic use
  • Linear Models
  • Magnetic Resonance Imaging / methods*
  • Mice
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / radiotherapy
  • Photochemotherapy / methods
  • Photosensitizing Agents / chemistry
  • Photosensitizing Agents / pharmacokinetics*
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / chemistry
  • Porphyrins / pharmacokinetics*
  • Porphyrins / therapeutic use
  • Radiometry
  • Verteporfin
  • Xenograft Model Antitumor Assays


  • Contrast Media
  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin